Efficiency and safety of Conbercept intravitreal injection combined with posterior sub-tenon injection of triamcinolone acetonide in macular edema due to central retinal vein occlusion

Status

Active, not recruiting

Phases

Phase 4

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR1900021193

Enrollment

Unknown

Registered

2019-02-01

Start date

2019-02-01

Completion date

Unknown

Last updated

2019-02-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Central retinal occlusion

Interventions

Group 1:Intravitreal injection of conbercept combined with posterior sub-tenon injection of triamcinolone acetonide

Group 2:Intravitreal injection of conbercept

Eligibility

Sex/Gender

All

Age

18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Diagnosed macular edema secondary to CRVO; 2. History of intravitreous injection; 3. Detailed case chart.

Exclusion criteria

Exclusion criteria: 1. Previous diagnosis of glaucoma or intraocular pressure higher than 21 mmHg; 2. Diagnosed NVG; 3. History of grid laser treatment; 4. Vitrectomized eye.

Design outcomes

Primary

Measure	Time frame
Release of macular edema;VA;	—

Countries

China

Contacts

Public ContactZhijun Wang

China-Japan Friendship Hospital

wangzj301@sina.com+86 13651268031

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026